AbbVie (NYSE:ABBV) traded higher in the premarket on Friday after setting its 2025 earnings outlook in line with expectations ...

AbbVie (ABBV) stock rallied today after the biopharmaceutical company posted its Q4 2024 earnings report. The good news ...

AbbVie (NYSE: ABBV) Q4 2024 Earnings Call Jan 31, 2025, 9:00 a.m. ET Good morning and thank you for standing by. Welcome to the AbbVie fourth-quarter 2024 Earnings Conference Call. [Operator ...

AbbVie Inc. (NYSE:ABBV) shares are trading higher on Friday. The company reported fourth-quarter adjusted earnings per share ...

Analysis of AbbVie Inc.'s Q4 2024 results, 2025 guidance, and future growth prospects, including the impact of clinical trial failures. Click for this ABBV update.

Shares of AbbVie ( ABBV 6.95%) were jumping 7.1% higher as of 11:10 a.m. ET on Friday after rising as much as 9.2% earlier in ...

He emphasized the consistent outperformance of the ex-Humira platform, which grew over 18% annually and accelerated to 22% growth in Q4. The company projects mid-single-digit revenue growth in 2025, ...

Reports Q4 revenue $15.1B, consensus $14.83B. “2024 was a year of significant progress for AbbVie (ABBV). Our growth platform delivered ...

AbbVie Inc. ABBV reported fourth-quarter 2024 adjusted earnings of $2.16 per share, which beat the Zacks Consensus Estimate of $2.13. The reported earnings also exceeded the company’s guidance of ...

AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship rheumatoid ...

AbbVie (ABBV), a large drug maker, is jumping 8% after the company provided significantly higher-than-expected 2025 earnings ...

Stocks have support on better-than-expected stock earnings news.  Apple is up more than +2% after forecasting a stronger-than-expected outlook.  Also, Atlassian is up more than +17% after reporting ...